vav-1 Antibody

Overview of Vav1 Antibody

Vav1 antibodies are immunoreagents designed to detect the Vav1 protein, which plays dual roles in immune regulation and cancer progression. Structurally, Vav1 contains calponin-homology (CH), Dbl-homology (DH), pleckstrin-homology (PH), SH2, and SH3 domains critical for signal transduction . These antibodies are widely used in techniques such as Western blot (WB), immunohistochemistry (IHC), immunoprecipitation (IP), and flow cytometry .

Cancer Prognosis and Metastasis

• Breast Cancer: High nuclear Vav1 expression in tumor cells correlates with improved prognosis in early-stage patients. In a study of 137 tumors, 51% classified as nVav1-high showed longer disease-free survival (mean nuclear positivity: 65.8%) .

• Pancreatic Cancer: Vav1 promotes metastasis by enhancing invasiveness. Azathioprine, a Vav1 inhibitor, reduced lung metastases by 50–70% in KPC mouse models (p48 Cre/+; LSL-Kras G12D/+ p53) .

Autoimmune and Inflammatory Diseases

• Rheumatoid Arthritis: Vav1-deficient mice exhibited reduced joint inflammation, synovial thickening, and proinflammatory cytokines (IL-6, TNF-α) in antigen-induced arthritis models .

• Endotoxemia: Vav1 suppresses LPS-induced IL-6 production in macrophages. Nuclear Vav1 binds HSF1 at the IL-6 promoter to inhibit transcription .

Mechanistic Insights

• Immune Synapse Formation: Vav1 regulates cytoskeletal reorganization in T and B cells, critical for immunological synapse assembly .

• Nuclear Localization: Vav1 localizes to nuclear speckles (co-localizing with SC-35) in breast cancer cells, suggesting transcriptional regulatory roles .

• Therapeutic Targeting: Azathioprine inhibits Vav1-driven invasion in pancreatic ductal adenocarcinoma (PDAC) by blocking GDP/GTP exchange activity .

Validation and Quality Control

• Specificity: CST #4657 and Abcam ab97574 show no cross-reactivity with Vav2/Vav3 .

• Band Confirmation: WB validation using Raji (Burkitt’s lymphoma) and Jurkat (T-cell leukemia) cell lines confirms detection of the 95–98 kDa Vav1 band .

Clinical Implications

Vav1 antibodies are pivotal for identifying Vav1 as a biomarker in cancer and autoimmune diseases. For example, nuclear Vav1 levels may guide breast cancer stratification, while pharmacologic inhibition of Vav1 could mitigate metastasis .